William Blair analyst Margaret Kaczor has maintained their bullish stance on PODD stock, giving a Buy rating on February 24.
Margaret Kaczor has given her Buy rating due to a combination of factors that highlight Insulet’s promising outlook. The company is poised for a favorable setup by 2025, driven by the momentum from the full-year launch of its Type 2 diabetes product. Additionally, Insulet is expected to benefit from advancements in automated insulin delivery (AID) systems, which are gaining traction in the market.
Furthermore, Insulet’s international expansion efforts are anticipated to contribute significantly to its growth. These strategic initiatives, coupled with the company’s robust performance in the fourth quarter, underpin Kaczor’s positive outlook on the stock. As a result, she sees strong potential for Insulet’s continued success and recommends a Buy rating.
In another report released on February 24, Bernstein also maintained a Buy rating on the stock with a $335.00 price target.